Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis
Status:
Completed
Trial end date:
1997-12-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Determine whether parenteral relaxin improves skin tightness, Raynaud's
phenomenon, digital morbidity, and digital ulcers in a patient with progressive systemic
sclerosis (scleroderma).
II. Determine whether relaxin decreases collagen production by fibroblasts in vivo and
cultured from skin biopsies.
Phase:
Phase 2
Details
Lead Sponsor:
National Center for Research Resources (NCRR)
Collaborators:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Stanford University